Pharma Antitrust Lawyer Recruiter

The settlement file did not go quiet when cash reverse payments became harder to write. The 15 January 2025 Bureau note says quantity restrictions — a cap on how much the settling generic may sell — appeared in 23 agreements covering 8 products across fiscal 2018 through 2021, including 11 agreements in fiscal 2021 alone. A counsel who has only negotiated a pure entry date, with no side deal and no volume cap, has a thinner record than the reports describe. The hiring test is documentary. Has this lawyer been on the settlement that was filed, including an agreement entered within 30 days of the primary settlement, which the Act has required since the October 2018 amendment the same note describes?

Orange Book listings are the second U.S. driver, and they have a 2024 court date and a 2025 agency date. On 20 December 2024 the U.S. Court of Appeals for the Federal Circuit affirmed an order that Teva delist five inhaler patents from the Orange Book, in Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC. The district court order was 10 June 2024. The patents claimed components of a metered-dose inhaler and, the courts held, did not claim the active ingredient. On 21 May 2025 the FTC sent a further round of warning letters and told the FDA it disputed more than 200 listings across 17 brand-name products, including asthma, diabetes, epinephrine autoinjector, and COPD drugs. The same release says the earlier challenges, in November 2023 and April 2024, led to delistings across 22 brand-name products. In April 2024 the Commission had disputed more than 300 listings across 20 products and written to 10 companies. A 2026 hire justified only by "patent litigation experience" misses the listing dispute. The lawyer who has written the certification, or the response to the FTC letter, is the one the brief is describing.

Pharmacy-benefit managers are the third driver, and the dates run into 2026. In July 2024 the FTC's interim staff report said the six largest pharmacy-benefit managers manage nearly 95 percent of prescriptions filled in the United States. The January 2025 second interim staff report said the three largest — Caremark, Express Scripts, and OptumRx — and their affiliated pharmacies generated more than $7.3 billion in revenue above the estimated acquisition cost of specialty generic drugs from 2017 through 2022, with markups of hundreds and thousands of percent. The same January 2025 release says the July 2024 report found that pharmacies affiliated with those three received 68 percent of specialty-drug dispensing revenue in 2023, up from 54 percent in 2016.

The enforcement dates are later than the study. In September 2024 the FTC sued those three managers and affiliated group-purchasing organizations over insulin rebates, as the analysis to aid public comment on the Caremark settlement states. On 4 February 2026 the FTC announced a settlement with Express Scripts. The Commission said the changes are expected to drive down patients' out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years. On 14 July 2026 the FTC announced a settlement with Caremark. The Commission said that settlement locks in place up to $8.5 billion in consumer savings over 10 years and unlocks up to $4.5 billion in additional patient savings over the same period from point-of-sale rebates. The case against Optum was withdrawn from adjudication so the Commission could consider a proposed consent. It is not a third announced settlement. Those dollar figures are the FTC's own expectations. They are not a measured saving, and they are not added together.

Hiring follows that sequence. A manufacturer needs someone who can tell the general counsel whether a settlement will be filed, whether a listing still meets the statute after 20 December 2024, and when to open a rebate inquiry. A pharmacy-benefit manager or a plan sponsor needs someone who has lived inside a formulary decision, not only a lawyer who has tried a Section 2 case about a different industry. Washington, New York, and Philadelphia are the published U.S. markets where that antitrust bar concentrates: Washington, New York, and Philadelphia. There is no separate New Jersey antitrust city page. A New Jersey headquarters still draws from those three markets.

Law firms hire when a partner who owns the pharmaceutical competition file is at capacity, when a counsel leaves for government or in-house, or when a platform has been renting the work. The test on the shortlist is the document. Has this lawyer filed an MMA settlement, defended or challenged an Orange Book listing after 20 December 2024, or lived through a rebate investigation? Tribunal experience matters on the litigation page. It does not substitute here. Of the 6 law-firm searches from January 2023 through September 2026, the median ran to week 18 because notice periods and conflicts run long, not because the market has no names.

Companies hire a different person. The in-house competition counsel decides which settlement gets filed, which listing comes off, and when outside counsel is instructed for a remedy or a government inquiry. The chief legal officer still signs the company's position. The in-house search line is the route for that seat. General counsel and chief legal officer searches, which are not this brief, reach a shortlist in 24 days and an accepted offer in a median of 11 weeks. On the 5 in-house competition seats in this series, the median shortlist was day 26 and the median accepted offer was week 12.

One of those five, in 2025, was a deputy general counsel for competition at an NYSE-listed pharmaceutical manufacturer in New Jersey. The search landed on that in-house median: shortlist on day 26, accepted offer in week 12. The deputy had signed reverse-payment settlements and had answered an Orange Book dispute. The company did not hire a patent trial lawyer and rename the role. The published antitrust markets for that corridor are New York and Philadelphia.

The shortlist had signed reverse-payment settlements and an Orange Book dispute. We did not need a patent trial lawyer under a competition title.

Of the 6 law-firm laterals, one in 2024 was a counsel moving to a Washington platform. The portable work was Orange Book defense and MMA settlement advice. The search landed on the law-firm median: shortlist on day 38, accepted offer in week 18. The notice period was 75 days. That file is one of the 6, not a separate count. The 75 days are that counsel's notice. They are not a market rule.

Benefit managers and plans look like the company hire, with a formulary calendar instead of a patent docket. The wrong profile is a drug-patent litigator who has never read a rebate contract. The wrong profile the other way is a healthcare regulatory lawyer with no competition file. UK and EU buyers are hiring for the judgment they now have to live with: a restriction-by-object settlement theory that survived appeal on 23 October 2025, and an excessive-price finding that survived appeal on 28 July 2026. Agency alumni are candidates in all four categories. Agency seats are outside this search.

2 of the 5 in-house seats drew a counter-offer. Acceptance across all 11 searches was 91 percent. Firm-wide in-house offer acceptance is 96 percent. Retention of placed in-house leaders is 97 percent at 12 months and 91 percent at 24 months. Retention for these 11 searches is the firm-wide figure, not a separate rate. Across all 11, the combined median shortlist was day 33 and the combined median to an accepted offer was week 15. Those combined medians sit between the subgroup medians. They are not an average of the two.

Every search is retained. There is no contingency. The fee is 25–30 percent of the hire's total first-year compensation. Thirty percent of that fee is paid as a retainer at engagement and kept if the client cancels. The replacement guarantee is 12 months on retained general counsel, chief legal officer, and chief compliance officer searches, and 6 months on other in-house searches. A competition counsel or deputy general counsel hired for pharmaceutical antitrust matters is in the 6-month category unless the role is itself a chief legal officer or chief compliance officer seat. We do not approach lawyers we have placed for as long as they stay in post, and we do not recruit from a client's legal department for 24 months after a mandate.

The method is the same on a firm lateral and an in-house competition seat, and the clock is not. Week one is the brief: whether the hire owns settlements, listings, rebate investigations, or a UK or EU pricing defense, and whether Hatch-Waxman patent trials stay with a different counsel. Mapping and private outreach follow. Nothing is sent to the client without the candidate's written consent. Conflicts are checked before the first call. Companies open that conversation at contact. A lawyer who wants a confidential conversation uses the CV form.

Measured on this series, from January 2023 through September 2026: in-house competition seats, 5 searches, median shortlist day 26, median accepted offer week 12. Law-firm laterals, 6 searches, median shortlist day 38, median accepted offer week 18. All 11 searches, median shortlist day 33, median accepted offer week 15. Acceptance 91 percent. Counter-offers on 2 of the 5 in-house seats. The New Jersey deputy general counsel search and the Washington counsel search are the two files described above. They are inside those medians, not additional searches.

A general counsel comparing this with a chief legal officer search should keep the books apart. Chief legal officer shortlists in 24 days and accepted offers in a median of 11 weeks are the officer search. Week 12 is the competition-counsel median on 5 seats. They are close. They are not the same mandate, and the samples are not the same sample.

Antitrust and competition recruiting is the parent. Antitrust litigation and unfair competition are the sibling specialisms. Pharmaceutical recruiting is the drug-development and Hatch-Waxman bench. Pharmaceuticals is the industry page for the companies that hire. City pages for the antitrust practice, which include this file and are not limited to it: Washington, New York, Philadelphia.

Read the antitrust attorney salary page before pricing the seat, and the countercyclical practice article for the wider practice. The brief here is who gets hired once the pharmaceutical competition seat is real: the 2025 settlement reports, the 2025 Orange Book letters, and the 2025 and 2026 court dates.